| __timestamp | Axsome Therapeutics, Inc. | Merus N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 3852327 |
| Thursday, January 1, 2015 | 2419289 | 839656 |
| Friday, January 1, 2016 | 6343648 | 4478145 |
| Sunday, January 1, 2017 | 7206691 | 16432324 |
| Monday, January 1, 2018 | 9351522 | 11890871 |
| Tuesday, January 1, 2019 | 13598030 | 34110000 |
| Wednesday, January 1, 2020 | 28896749 | 35781000 |
| Friday, January 1, 2021 | 66646205 | 40896000 |
| Saturday, January 1, 2022 | 159253661 | 52200000 |
| Sunday, January 1, 2023 | 323123000 | 59836000 |
| Monday, January 1, 2024 | 411359000 |
Cracking the code
In the competitive world of biotechnology, operational efficiency is key. This analysis of Selling, General, and Administrative (SG&A) expenses from 2014 to 2023 reveals intriguing trends for Axsome Therapeutics, Inc. and Merus N.V. Over this period, Axsome's SG&A expenses skyrocketed by over 23,000%, peaking in 2023. This surge reflects their aggressive expansion and investment in operational infrastructure. In contrast, Merus N.V. experienced a more modest increase of around 1,500%, indicating a steadier growth trajectory. Notably, both companies saw significant jumps in 2020, likely due to pandemic-related adjustments. By 2023, Axsome's expenses were over five times higher than Merus's, highlighting differing strategic priorities. This data underscores the dynamic nature of the biotech sector, where financial strategies can vary widely, impacting long-term success.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Breaking Down SG&A Expenses: Amgen Inc. vs Merus N.V.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Merus N.V.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
SG&A Efficiency Analysis: Comparing Walgreens Boots Alliance, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Blueprint Medicines Corporation and Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. or Perrigo Company plc: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Axsome Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
Veracyte, Inc. vs Merus N.V.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Merus N.V. or Galapagos NV